What is Medpace Holdings Intrinsic Value: Projected FCF?
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-05-07), Medpace Holdings's Intrinsic Value: Projected FCF is $141.78. The stock price of Medpace Holdings is $403.54. Therefore, Medpace Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 2.9.
The historical rank and industry rank for Medpace Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:
MEDP'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.67 Med: 2.15 Max: 3.42
Current: 2.85
During the past 11 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Medpace Holdings was 3.42. The lowest was 1.67. And the median was 2.15.
MEDP's Price-to-Projected-FCF is ranked worse than 77.89% of 95
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.63
vs MEDP: 2.85
Medpace Holdings Intrinsic Value: Projected FCF Historical Data
The historical data trend for Medpace Holdings's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medpace Holdings's Intrinsic Value: Projected FCF
For the Diagnostics & Research subindustry, Medpace Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings's Price-to-Projected-FCF Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Medpace Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
403.54
/
141.77784477119
=
2.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of Medpace Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Medpace Holdings (Medpace Holdings) Business Description
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEDP has been successfully added to your 